{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T08:47:27Z","timestamp":1792658847989,"version":"4.5.0"},"reference-count":86,"publisher":"Elsevier BV","issue":"25","license":[{"start":{"date-parts":[[2013,12,1]],"date-time":"2013-12-01T00:00:00Z","timestamp":1385856000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,12,1]],"date-time":"2013-12-01T00:00:00Z","timestamp":1385856000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2014,12,24]],"date-time":"2014-12-24T00:00:00Z","timestamp":1419379200000},"content-version":"vor","delay-in-days":388,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American College of Cardiology"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1016\/j.jacc.2013.10.031","type":"journal-article","created":{"date-parts":[[2013,12,16]],"date-time":"2013-12-16T16:21:34Z","timestamp":1387210894000},"page":"D60-D72","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":556,"special_numbering":"S","title":["Updated Treatment Algorithm of Pulmonary Arterial Hypertension"],"prefix":"10.1016","volume":"62","author":[{"given":"Nazzareno","family":"Gali\u00e8","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul A.","family":"Corris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adaani","family":"Frost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reda E.","family":"Girgis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Granton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi Cheng","family":"Jing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Klepetko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D.","family":"McGoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vallerie V.","family":"McLaughlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioana R.","family":"Preston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lewis J.","family":"Rubin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio","family":"Sandoval","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Werner","family":"Seeger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Keogh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacc.2013.10.031_bib1","first-page":"739","article-title":"Pulmonary hypertension\u2014advances in medical and surgical interventions","volume":"17","author":"McLaughlin","year":"1998","journal-title":"J\u00a0Heart Lung Transplant"},{"key":"10.1016\/j.jacc.2013.10.031_bib2","doi-asserted-by":"crossref","first-page":"S81","DOI":"10.1016\/j.jacc.2004.02.038","article-title":"Comparative analysis of clinical trials and evidence-based treatment algorithm in pulmonary arterial hypertension","volume":"43","author":"Galie","year":"2004","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2013.10.031_bib3","doi-asserted-by":"crossref","first-page":"S78","DOI":"10.1016\/j.jacc.2009.04.017","article-title":"Updated evidence-based treatment algorithm in pulmonary arterial hypertension","volume":"54","author":"Barst","year":"2009","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2013.10.031_bib4","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1093\/eurheartj\/ehp297","article-title":"Guidelines on diagnosis and treatment of pulmonary hypertension: the Task Force on Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology and of the European Respiratory Society","volume":"30","author":"Gali\u00e8","year":"2009","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2013.10.031_bib5","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1093\/eurheartj\/ehp022","article-title":"A\u00a0meta-analysis of randomized controlled trials in pulmonary arterial hypertension","volume":"30","author":"Galie","year":"2009","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2013.10.031_bib6","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1159\/000334431","article-title":"Combination therapy in pulmonary arterial hypertension: a meta-analysis","volume":"120","author":"Bai","year":"2011","journal-title":"Cardiology"},{"key":"10.1016\/j.jacc.2013.10.031_bib7","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1183\/09031936.00141211","article-title":"Pregnancy outcomes in pulmonary arterial hypertension in the modern management era","volume":"40","author":"Jais","year":"2012","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jacc.2013.10.031_bib8","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1161\/CIRCULATIONAHA.106.618397","article-title":"Exercise and respiratory training improve exercise capacity and quality of life in patients with severe chronic pulmonary hypertension","volume":"114","author":"Mereles","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2013.10.031_bib9","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1183\/09031936.00027909","article-title":"Effects of exercise training in patients with idiopathic pulmonary arterial hypertension","volume":"34","author":"de Man","year":"2009","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jacc.2013.10.031_bib10","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1159\/000322475","article-title":"Effect of exercise and respiratory training on clinical progression and survival in patients with severe chronic pulmonary hypertension","volume":"81","author":"Grunig","year":"2011","journal-title":"Respiration"},{"key":"10.1016\/j.jacc.2013.10.031_bib11","doi-asserted-by":"crossref","first-page":"R148","DOI":"10.1186\/ar3883","article-title":"Exercise training in pulmonary arterial hypertension associated with connective tissue diseases","volume":"14","author":"Grunig","year":"2012","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jacc.2013.10.031_bib12","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1183\/09031936.00123711","article-title":"Safety and efficacy of exercise training in various forms of pulmonary hypertension","volume":"40","author":"Grunig","year":"2012","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jacc.2013.10.031_bib13","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.ijcard.2012.09.036","article-title":"Efficacy of exercise training in pulmonary arterial hypertension associated with congenital heart disease","volume":"168","author":"Becker-Grunig","year":"2013","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jacc.2013.10.031_bib14","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.rmed.2013.02.006","article-title":"Effect of aerobic exercise training on fatigue and physical activity in patients with pulmonary arterial hypertension","volume":"107","author":"Weinstein","year":"2013","journal-title":"Respir Med"},{"key":"10.1016\/j.jacc.2013.10.031_bib15","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1378\/chest.12-0993","article-title":"Benefits of intensive treadmill exercise training on cardiorespiratory function and quality of life in patients with pulmonary hypertension","volume":"143","author":"Chan","year":"2013","journal-title":"Chest"},{"key":"10.1016\/j.jacc.2013.10.031_bib16","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1056\/NEJM199905273402106","article-title":"The association between hospital volume and survival after acute myocardial infarction in elderly patients","volume":"340","author":"Thiemann","year":"1999","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2013.10.031_bib17","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1183\/09059180.00004910","article-title":"Optimising the management of pulmonary arterial hypertension patients: emergency treatments","volume":"19","author":"Delcroix","year":"2010","journal-title":"Eur Respir Rev"},{"issue":"4 Suppl","key":"10.1016\/j.jacc.2013.10.031_bib18","first-page":"s81","article-title":"Care organization for pulmonary arterial hypertension in developed countries: a survey","volume":"31","author":"Delcroix","year":"2012","journal-title":"J\u00a0Heart Lung Transplant"},{"key":"10.1016\/j.jacc.2013.10.031_bib19","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1183\/09031936.00169608","article-title":"Iloprost for pulmonary vasodilator testing in idiopathic pulmonary arterial hypertension","volume":"33","author":"Jing","year":"2009","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jacc.2013.10.031_bib20","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1056\/NEJM199306173282402","article-title":"Expression of endothelin-1 in the lungs of patients with pulmonary hypertension","volume":"328","author":"Giaid","year":"1993","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2013.10.031_bib21","doi-asserted-by":"crossref","first-page":"464","DOI":"10.7326\/0003-4819-114-6-464","article-title":"Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease?","volume":"114","author":"Stewart","year":"1991","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jacc.2013.10.031_bib22","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.cardiores.2003.11.026","article-title":"The endothelin system in pulmonary arterial hypertension","volume":"61","author":"Galie","year":"2004","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.jacc.2013.10.031_bib23","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.jacc.2005.04.050","article-title":"Ambrisentan therapy for pulmonary arterial hypertension","volume":"46","author":"Galie","year":"2005","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2013.10.031_bib24","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1161\/CIRCULATIONAHA.107.742510","article-title":"Ambrisentan for the treatment of pulmonary arterial hypertension. Results of the Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy (ARIES) study 1 and 2","volume":"117","author":"Galie","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2013.10.031_bib25","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1378\/chest.08-1028","article-title":"Ambrisentan therapy in patients with pulmonary arterial hypertension who discontinued bosentan or sitaxsentan due to liver function test abnormalities","volume":"135","author":"McGoon","year":"2009","journal-title":"Chest"},{"key":"10.1016\/j.jacc.2013.10.031_bib26","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/S0140-6736(01)06250-X","article-title":"Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study","volume":"358","author":"Channick","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2013.10.031_bib27","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMoa012212","article-title":"Bosentan therapy for pulmonary arterial hypertension","volume":"346","author":"Rubin","year":"2002","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2013.10.031_bib28","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1183\/09031936.04.00028404","article-title":"Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2","volume":"24","author":"Humbert","year":"2004","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jacc.2013.10.031_bib29","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1016\/S0140-6736(08)60919-8","article-title":"Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial","volume":"371","author":"Gali\u00e8","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2013.10.031_bib30","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1161\/CIRCULATIONAHA.106.630715","article-title":"Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study","volume":"114","author":"Galie","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2013.10.031_bib31","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1213917","article-title":"Macitentan and morbidity and mortality in pulmonary arterial hypertension","volume":"369","author":"Pulido","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2013.10.031_bib32","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1056\/NEJM199507273330403","article-title":"Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension","volume":"333","author":"Giaid","year":"1995","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2013.10.031_bib33","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1056\/NEJMoa1209655","article-title":"Riociguat for the treatment of pulmonary arterial hypertension","volume":"369","author":"Ghofrani","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2013.10.031_bib34","first-page":"A3530","article-title":"A\u00a0placebo-controlled, double-blind phase II interaction study to evaluate blood pressure following addition of riociguat to patients with symptomatic pulmonary arterial hypertension (PAH) receiving sildenafil (PATENT PLUS)","volume":"187","author":"Galie","year":"2013","journal-title":"Am J Resp Crit Care Med"},{"key":"10.1016\/j.jacc.2013.10.031_bib35","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1164\/rccm.200411-1587OC","article-title":"Antiproliferative effects of phosphodiesterase ype 5 inhibition in human pulmonary artery cells","volume":"172","author":"Wharton","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jacc.2013.10.031_bib36","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s00395-004-0504-5","article-title":"Antiproliferative effect of sildenafil on human pulmonary artery smooth muscle cells","volume":"100","author":"Tantini","year":"2005","journal-title":"Basic Res Cardiol"},{"key":"10.1016\/j.jacc.2013.10.031_bib37","first-page":"1488","article-title":"Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study","volume":"44","author":"Ghofrani","year":"2004","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2013.10.031_bib38","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1056\/NEJMoa050010","article-title":"Sildenafil citrate therapy for pulmonary arterial hypertension","volume":"353","author":"Galie","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2013.10.031_bib39","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/j.jacc.2003.10.056","article-title":"Clinical efficacy of sildenafil in primary pulmonary hypertension: a randomized, placebo-controlled, double-blind, crossover study","volume":"43","author":"Sastry","year":"2004","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2013.10.031_bib40","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1093\/eurheartj\/ehq011","article-title":"Combination therapy with bosentan and sildenafil in Eisenmenger syndrome: a randomized, placebo-controlled, double-blinded trial","volume":"31","author":"Iversen","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2013.10.031_bib41","doi-asserted-by":"crossref","first-page":"851.e1","DOI":"10.1016\/j.ahj.2005.09.006","article-title":"A\u00a0randomized, placebo-controlled, double-blind, crossover study to evaluate the efficacy of oral sildenafil therapy in severe pulmonary artery hypertension","volume":"151","author":"Singh","year":"2006","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacc.2013.10.031_bib42","doi-asserted-by":"crossref","first-page":"521","DOI":"10.7326\/0003-4819-149-8-200810210-00004","article-title":"Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension","volume":"149","author":"Simonneau","year":"2008","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jacc.2013.10.031_bib43","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.1365-2125.2010.03831.x","article-title":"Safety, tolerability and pharmacokinetics of an intravenous bolus of sildenafil in patients with pulmonary arterial hypertension","volume":"71","author":"Vachiery","year":"2011","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jacc.2013.10.031_bib44","doi-asserted-by":"crossref","first-page":"2894","DOI":"10.1161\/CIRCULATIONAHA.108.839274","article-title":"Tadalafil therapy for pulmonary arterial hypertension","volume":"119","author":"Galie","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2013.10.031_bib45","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1164\/rccm.201101-0093OC","article-title":"Vardenafil in pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled study","volume":"183","author":"Jing","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jacc.2013.10.031_bib46","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1164\/rccm.201001-0123OC","article-title":"Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy","volume":"182","author":"Ghofrani","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jacc.2013.10.031_bib47","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1161\/CIRCULATIONAHA.112.000765","article-title":"Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study","volume":"127","author":"Hoeper","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2013.10.031_bib48","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/S0026-895X(25)10547-6","article-title":"Activation of thromboxane and prostacyclin receptors elicits opposing effects on vascular smooth muscle cell growth and mitogen-activated protein kinase signaling cascades","volume":"48","author":"Jones","year":"1995","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.jacc.2013.10.031_bib49","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1056\/NEJM199207093270202","article-title":"An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension","volume":"327","author":"Christman","year":"1992","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2013.10.031_bib50","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/BF03256644","article-title":"Prostanoids for pulmonary arterial hypertension","volume":"2","author":"Galie","year":"2003","journal-title":"Am J Respir Med"},{"key":"10.1016\/j.jacc.2013.10.031_bib51","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1016\/S0735-1097(02)01786-2","article-title":"Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomised, double-blind placebo-controlled trial","volume":"39","author":"Galie","year":"2002","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2013.10.031_bib52","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1016\/S0735-1097(03)00463-7","article-title":"Beraprost therapy for pulmonary arterial hypertension","volume":"41","author":"Barst","year":"2003","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2013.10.031_bib53","doi-asserted-by":"crossref","first-page":"485","DOI":"10.7326\/0003-4819-112-7-485","article-title":"Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial","volume":"112","author":"Rubin","year":"1990","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jacc.2013.10.031_bib54","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1056\/NEJM199602013340504","article-title":"A\u00a0comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension","volume":"334","author":"Barst","year":"1996","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2013.10.031_bib55","doi-asserted-by":"crossref","first-page":"425","DOI":"10.7326\/0003-4819-132-6-200003210-00002","article-title":"Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial","volume":"132","author":"Badesch","year":"2000","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jacc.2013.10.031_bib56","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1056\/NEJMoa020204","article-title":"Inhaled iloprost in severe pulmonary hypertension","volume":"347","author":"Olschewski","year":"2002","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2013.10.031_bib57","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1164\/rccm.200603-358OC","article-title":"Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension","volume":"174","author":"McLaughlin","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jacc.2013.10.031_bib58","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1183\/09031936.06.00057906","article-title":"Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension","volume":"4","author":"Hoeper","year":"2006","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jacc.2013.10.031_bib59","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1136\/hrt.80.2.151","article-title":"Long-term intravenous prostaglandin (epoprostenol or iloprost) for treatment of severe pulmonary hypertension","volume":"80","author":"Higenbottam","year":"1998","journal-title":"Heart"},{"key":"10.1016\/j.jacc.2013.10.031_bib60","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1164\/ajrccm.165.6.2106079","article-title":"Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension. A double-blind, randomized, placebo-controlled trial","volume":"165","author":"Simonneau","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jacc.2013.10.031_bib61","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.healun.2009.09.005","article-title":"Exercise improvement and plasma biomarker changes with intravenous treprostinil therapy for pulmonary arterial hypertension: a placebo-controlled trial","volume":"29","author":"Hiremath","year":"2010","journal-title":"J\u00a0Heart Lung Transplant"},{"key":"10.1016\/j.jacc.2013.10.031_bib62","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/j.jacc.2010.01.027","article-title":"Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial","volume":"55","author":"McLaughlin","year":"2010","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2013.10.031_bib63","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1378\/chest.11-2212","article-title":"Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and\/or phosphodiesterase type 5 inhibitor therapy (the freedom-c study): a randomized controlled trial","volume":"142","author":"Tapson","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.jacc.2013.10.031_bib64","first-page":"1363","article-title":"Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and\/or phosphodiesterase type 5 inhibitor therapy (The FREEDOM-C2 Study): a randomized controlled trial","volume":"142","author":"Tapson","year":"2013","journal-title":"Chest"},{"key":"10.1016\/j.jacc.2013.10.031_bib65","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1161\/CIRCULATIONAHA.112.124388","article-title":"Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: a randomized, controlled trial","volume":"127","author":"Jing","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2013.10.031_bib66","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1183\/09031936.00137511","article-title":"Selexipag, an oral, selective IP receptor agonist for the treatment of pulmonary arterial hypertension","volume":"40","author":"Simonneau","year":"2012","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jacc.2013.10.031_bib67","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1093\/eurheartj\/ehq152","article-title":"Pulmonary arterial hypertension: from the kingdom of the near-dead to multiple clinical trial meta-analyses","volume":"31","author":"Galie","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2013.10.031_bib68","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1183\/09031936.00092311","article-title":"The prognostic impact of follow-up assessments in patients with idiopathic pulmonary arterial hypertension","volume":"39","author":"Nickel","year":"2012","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jacc.2013.10.031_bib69","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.healun.2011.11.002","article-title":"Usefulness of first-line combination therapy with epoprostenol and bosentan in pulmonary arterial hypertension: An observational study","volume":"31","author":"Kemp","year":"2012","journal-title":"J\u00a0Heart Lung Transplant"},{"key":"10.1016\/j.jacc.2013.10.031_bib70","doi-asserted-by":"crossref","first-page":"S67","DOI":"10.1016\/j.jacc.2009.04.016","article-title":"Interventional and surgical modalities of treatment in pulmonary arterial hypertension","volume":"54","author":"Keogh","year":"2009","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2013.10.031_bib71","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/S0735-1097(02)02012-0","article-title":"Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival","volume":"40","author":"Sitbon","year":"2002","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2013.10.031_bib72","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1161\/01.CIR.0000029100.82385.58","article-title":"Survival in primary pulmonary hypertension: the impact of epoprostenol therapy","volume":"106","author":"McLaughlin","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2013.10.031_bib73","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/j.healun.2006.06.001","article-title":"Registry of the International Society for Heart and Lung Transplantation: twenty-third official adult lung and heart lung transplantation report\u20142006","volume":"25","author":"Trulock","year":"2006","journal-title":"J\u00a0Heart Lung Transplant"},{"key":"10.1016\/j.jacc.2013.10.031_bib74","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/j.athoracsur.2008.05.049","article-title":"Long-term outcome of lung and heart-lung transplantation for idiopathic pulmonary arterial hypertension","volume":"86","author":"Toyoda","year":"2008","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.jacc.2013.10.031_bib75","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.ejcts.2010.02.039","article-title":"Long-term outcome of double-lung and heart-lung transplantation for pulmonary hypertension: a comparative retrospective study of 219 patients","volume":"38","author":"Fadel","year":"2010","journal-title":"Eur J Cardiothorac Surg"},{"key":"10.1016\/j.jacc.2013.10.031_bib76","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.jtcvs.2011.08.055","article-title":"Outcome of patients with pulmonary arterial hypertension referred for lung transplantation: a 14-year single-center experience","volume":"143","author":"de Perrot","year":"2012","journal-title":"J\u00a0Thorac Cardiovasc Surg"},{"key":"10.1016\/j.jacc.2013.10.031_bib77","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/j.healun.2012.08.004","article-title":"The Registry of the International Society for Heart and Lung Transplantation: 29th official adult lung and heart-lung transplant report\u20142012","volume":"31","author":"Christie","year":"2012","journal-title":"J\u00a0Heart Lung Transplant"},{"key":"10.1016\/j.jacc.2013.10.031_bib78","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/S1053-2498(01)00420-X","article-title":"Heart-lung or lung transplantation for Eisenmenger syndrome","volume":"21","author":"Waddell","year":"2002","journal-title":"J\u00a0Heart Lung Transplant"},{"key":"10.1016\/j.jacc.2013.10.031_bib79","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.jtcvs.2004.07.058","article-title":"Repair of congenital heart lesions combined with lung transplantation for the treatment of severe pulmonary hypertension: a 13-year experience","volume":"129","author":"Choong","year":"2005","journal-title":"J\u00a0Thorac Cardiovasc Surg"},{"key":"10.1016\/j.jacc.2013.10.031_bib80","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1164\/rccm.201109-1599OC","article-title":"Extracorporeal membrane oxygenation in awake patients as bridge to lung transplantation","volume":"185","author":"Fuehner","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jacc.2013.10.031_bib81","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S0735-1097(98)00238-1","article-title":"Graded balloon dilation atrial septostomy in severe primary pulmonary hypertension. A therapeutic alternative for patients nonresponsive to vasodilator treatment","volume":"32","author":"Sandoval","year":"1998","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2013.10.031_bib82","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1378\/chest.06-1227","article-title":"Atrial septostomy in treatment of end-stage right heart failure in patients with pulmonary hypertension","volume":"131","author":"Kurzyna","year":"2007","journal-title":"Chest"},{"key":"10.1016\/j.jacc.2013.10.031_bib83","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1378\/chest.07-1222","article-title":"Long-term follow-up of a fenestrated Amplatzer atrial septal occluder in pulmonary arterial hypertension","volume":"133","author":"Althoff","year":"2008","journal-title":"Chest"},{"key":"10.1016\/j.jacc.2013.10.031_bib84","doi-asserted-by":"crossref","first-page":"2973","DOI":"10.1002\/sim.5403","article-title":"Biomarkers and surrogate endpoints in clinical trials","volume":"31","author":"Fleming","year":"2012","journal-title":"Statist Med"},{"key":"10.1016\/j.jacc.2013.10.031_bib85","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1377\/hlthaff.24.1.67","article-title":"Surrogate endpoints and FDA accelerated approval process","volume":"24","author":"Fleming","year":"2005","journal-title":"Health Affairs"},{"key":"10.1016\/j.jacc.2013.10.031_bib86","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/j.jacc.2012.01.083","article-title":"Do changes of 6-minute walk distance predict clinical events in patients with pulmonary arterial hypertension?: A meta-analysis of 22 randomized trials","volume":"60","author":"Savarese","year":"2012","journal-title":"J\u00a0Am Coll Cardiol"}],"container-title":["Journal of the American College of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109713058749?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109713058749?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T13:03:56Z","timestamp":1760015036000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109713058749"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12]]},"references-count":86,"journal-issue":{"issue":"25","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["S0735109713058749"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2013.10.031","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2013,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Updated Treatment Algorithm of Pulmonary Arterial Hypertension","name":"articletitle","label":"Article Title"},{"value":"Journal of the American College of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2013.10.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}